ABSTRACT
Objective@#To observe the clinical efficacy and adverse reactions of pemetrexed in combination with nedaplatin or cisplatin in the treatment of advanced non-small cell lung cancer(NSCLC).@*Methods@#85 patients with stage Ⅲ B/IV NSCLC diagnosed by pathology or cytology were randomly divided into two groups by random double blind method.The study group(45cases) was treated with pemetrexed combined with nedaplatin, and the control group(40cases) was given pemetrexed combined with cisplatin chemotherapy.The specific method was pemetrexed 500mg/m2, the first day of intravenous infusion, cisplatin 75mg/m2 or nedaplatin 80mg/m2, divided into 3 times, the 2nd, 3rd, 4th day, intravenous infusion, every 21d for a cycle.At the end of the chemotherapy, the efficacy and adverse reaction were analyzed.The patients were followed up to record no progress survival and one-year survival rate.@*Results@#Among 85 patients, there were 35 cases of partial remission(PR), 35 cases of stable(SD) and 15 cases of progression(PD), the total effective rate(ORR) was 42.2%, the disease control rate(DCR) was 82.2%.There were no statistically significant differences in ORR and DCR between the two groups(χ2=0.043, 0.001, all P>0.05). As to the adverse reactions, the incidence rates of the decreased number of white blood cells (42.2% vs.25.0%), the decreased number of neutrophils (35.6% vs.17.5%), the decreased number of platelets (42.2% vs.15.0%), anemia(31.1% vs.12.5%), nausea/vomiting(22.2% vs.70.0%) between the two groups had statistically significant differences (χ2=9.319, 4.664, 7.559, 4.226, 19.556, all P<0.05). There were no significant differences in progression-free survival and one-year survival rate between the two groups (χ2=0.717, 0.226, all P>0.05).@*Conclusion@#There was no statistically significant difference in the efficacy between pemetrexed combined with nedaplatin or cisplatin, non-squamous cell carcinoma patients get a better therapeutic effect.Nedaplatin is more likely to cause myelosuppression and intestinal side effects of cisplatin are more common.
ABSTRACT
Objective To investigate the relationship between expression of E -cad and IGF -1R and the recurrence of patients with primary hepatocellular carcinoma (HCC)who underwent liver resection.Methods The clinical data of 91 cases of primary HCC underwent liver resection from January 2010 to December 2012 were analyzed retrospectively.The expression of E -cad and IGF -1R was detected by RT -PCR,and the relationship between expression of E -cad and IGF -1R and the recurrence of patients was analyzed.Results The expression of E -cad was obviously lower in HCC tissues than that in normal liver tissues,with the expression percentage of 38.7% vs. 75.0%.The recurrence rate of E -cad negative group was higher(71.1%).The TNM Ⅱ -Ⅳ stage (χ2 =7.161, P =0.009)and liver capsule invasion (χ2 =5.144,P =0.036)in E -cad negative group were higher than E -cad positive group.The expression of IGF -1R was obviously higher in HCC tissues than that in normal liver tissues,with the expression percentage of 66.1% vs.20.0%.The recurrence rate of IGF -1R negative group was higher(68.3%). The TNMⅡ-Ⅳ stage (χ2 =4.195,P =0.014),liver capsule invasion (χ2 =5.144,P =0.036),non -tumor capsularin (χ2 =7.201,P =0.012)and PVTT(χ2 =6.538,P =0.032)in E -cad negative group were higher than E -cad positive group.And there was negative correlation between the expression of E -cad and IGF -1R(χ2 =14.329,P =0.000).Conclusion The mRNA expression of E -cad in the tissues of HCC is obviously lower than normal liver tissues.The mRNA expression of IGF -1R in the tissues of HCC is obviously higher than normal liver tissues.The expressions of E -cad and IGF -1R are associated with the degree of local invasion and malignant.The E -cad and IGF -1R expression is correlated in the tissues of HCC,which means that E -cad and IGF -1R play synergistic effect in HCC genesis.